Heron Therapeutics (HRTX) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Rein Therapeutics (RNTX) has outperformed Heron Therapeutics (HRTX) over the past year, losing 44.7% versus a loss of 73.5%. Over five years, RNTX leads with a -96.2% price change compared with -96.6% for HRTX. Heron Therapeutics is the larger company by market cap ($68.0 million vs $66.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | RNTX |
|---|---|---|
| Share price | $0.3582 | $0.7693 |
| Market cap | $68.01M | $66.37M |
| 1-day change | -6.79% | -2.46% |
| YTD return | -72.45% | -33.68% |
| 1-year return | -73.47% | -44.65% |
| 5-year return | -96.62% | -96.19% |
| EPS (TTM) | $-0.18 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.58 | $2.18 |
| 52-week low | $0.26 | $0.694 |
| Distance from 52-week high | -77.33% | -64.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +1854.22% | +679.93% |
| Average volume | 2.58M | 428.25K |
| Shares outstanding | 189.85M | 86.27M |
| Employees | 128 | 10 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNTX has outperformed HRTX by 28.8 percentage points over the past year.
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Healthcare · Biotechnology · 128 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Healthcare · Biotechnology · 10 employees
HRTX vs RNTX FAQ
Which is bigger, Heron Therapeutics or Rein Therapeutics?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $68.01M compared with $66.37M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, HRTX or RNTX?
RNTX returned -44.65% over the past 12 months, compared with -73.47% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.